-
Uncategorized2 weeks ago
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.
-
Uncategorized2 weeks agoOpinion: Science and the public are learning the wrong lessons from Covid
Covid fatigue is real, but policymakers and policy influencers need to wake up to something important: Post-pandemic polarization threatens to lock our memories into attractive, untrue...
-
Uncategorized2 weeks agoOpinion: How a controversial rule could hurt the NIH’s ability to manage risk
The Trump administration is centralizing and politicizing science grantmaking to an unprecedented degree. Most recently, the Office of Management and Budget proposed a rule to require...
-
Uncategorized2 weeks ago
Early Genomic Indicators of Praziquantel Resistance in Schistosoma mansoni
Early Genomic Indicators of Praziquantel Resistance in Schistosoma mansoni
-
Uncategorized2 weeks ago
Towards an enzyme cascade synthesis of the bulk chemical acrylic acid
Post Content
-
Uncategorized2 weeks ago
ENVnet provides a global molecular resource of dissolved organic matter
Nature Biotechnology, Published online: 21 July 2026; doi:10.1038/s41587-026-03230-0 A resource of dissolved organic matter illuminates carbon and microbial life in Earth’s ecosystems.
-
Uncategorized2 weeks ago
Flu Virus Interaction with Host Cell Machinery Mapped Inside Infected Cells
Flu Virus Interaction with Host Cell Machinery Mapped Inside Infected Cells
-
Uncategorized2 weeks agoFDA still focused on lettuce supplier as source of parasite, despite faulty test result
WASHINGTON — Federal health officials said Monday they remain focused on lettuce from Taylor Farms as the source of a multistate outbreak of a diarrhea-causing parasite, despite inaccurate test...
-
Uncategorized2 weeks agoProtein Protects Against Tau Tangles, Synaptic Loss in Mouse Model of Tauopathy
Protein Protects Against Tau Tangles, Synaptic Loss in Mouse Model of Tauopathy
-
Uncategorized2 weeks agoTempus to buy cancer test-maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
